Global Radiopharmaceuticals for PET and SPECT Imaging Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Radiopharmaceuticals for PET and SPECT Imaging market size was valued at US$ 7203 million in 2025 and is forecast to a readjusted size of US$ 11227 million by 2032 with a CAGR of 6.5% during review period.
Radiopharmaceuticals for PET and SPECT Imaging are specialized radioactive compounds used as diagnostic tracers in nuclear medicine imaging procedures. These agents consist of a biologically active molecule labeled with a radionuclide, allowing physicians to visualize physiological, biochemical, and molecular processes within the body. In Positron Emission Tomography (PET), commonly used isotopes include fluorine-18, carbon-11, gallium-68, and zirconium-89, while Single Photon Emission Computed Tomography (SPECT) primarily utilizes technetium-99m, iodine-123, and thallium-201. These radiopharmaceuticals are widely employed in oncology, cardiology, neurology, and infection imaging, enabling early disease detection, diagnosis, treatment planning, and therapeutic monitoring.
The global Fluorine-18 market is experiencing steady expansion, driven primarily by the rising prevalence of chronic diseases such as cancer, Alzheimer?s, and cardiovascular disorders. As the gold standard radionuclide for Positron Emission Tomography (PET) imaging, Fluorine-18 benefits from its 110-minute half-life, which allows for efficient centralized production and distribution. Market growth is further propelled by the adoption of precision medicine, the expansion of cyclotron infrastructure, and the continuous development of novel radiotracers beyond traditional FDG. While North America remains the dominant region due to its advanced healthcare infrastructure and high utilization of PET/CT systems, the Asia-Pacific region is emerging as the fastest-growing market, fueled by significant investments in nuclear medicine and increasing healthcare accessibility. Future market trends emphasize the integration of AI in diagnostic imaging, the rise of 'theranostics,' and a strategic shift toward localized, hospital-adjacent cyclotron facilities to optimize supply chain efficiency.
This report is a detailed and comprehensive analysis for global Radiopharmaceuticals for PET and SPECT Imaging market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radiopharmaceuticals for PET and SPECT Imaging market size and forecasts, in consumption value ($ Million), 2021-2032
Global Radiopharmaceuticals for PET and SPECT Imaging market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Radiopharmaceuticals for PET and SPECT Imaging market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Radiopharmaceuticals for PET and SPECT Imaging market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Radiopharmaceuticals for PET and SPECT Imaging market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Radiopharmaceuticals for PET and SPECT Imaging are specialized radioactive compounds used as diagnostic tracers in nuclear medicine imaging procedures. These agents consist of a biologically active molecule labeled with a radionuclide, allowing physicians to visualize physiological, biochemical, and molecular processes within the body. In Positron Emission Tomography (PET), commonly used isotopes include fluorine-18, carbon-11, gallium-68, and zirconium-89, while Single Photon Emission Computed Tomography (SPECT) primarily utilizes technetium-99m, iodine-123, and thallium-201. These radiopharmaceuticals are widely employed in oncology, cardiology, neurology, and infection imaging, enabling early disease detection, diagnosis, treatment planning, and therapeutic monitoring.
The global Fluorine-18 market is experiencing steady expansion, driven primarily by the rising prevalence of chronic diseases such as cancer, Alzheimer?s, and cardiovascular disorders. As the gold standard radionuclide for Positron Emission Tomography (PET) imaging, Fluorine-18 benefits from its 110-minute half-life, which allows for efficient centralized production and distribution. Market growth is further propelled by the adoption of precision medicine, the expansion of cyclotron infrastructure, and the continuous development of novel radiotracers beyond traditional FDG. While North America remains the dominant region due to its advanced healthcare infrastructure and high utilization of PET/CT systems, the Asia-Pacific region is emerging as the fastest-growing market, fueled by significant investments in nuclear medicine and increasing healthcare accessibility. Future market trends emphasize the integration of AI in diagnostic imaging, the rise of 'theranostics,' and a strategic shift toward localized, hospital-adjacent cyclotron facilities to optimize supply chain efficiency.
This report is a detailed and comprehensive analysis for global Radiopharmaceuticals for PET and SPECT Imaging market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radiopharmaceuticals for PET and SPECT Imaging market size and forecasts, in consumption value ($ Million), 2021-2032
Global Radiopharmaceuticals for PET and SPECT Imaging market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Radiopharmaceuticals for PET and SPECT Imaging market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Radiopharmaceuticals for PET and SPECT Imaging market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Radiopharmaceuticals for PET and SPECT Imaging
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Radiopharmaceuticals for PET and SPECT Imaging market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Positron Emitters
- Gamma Emitters
- Cyclotron-produced
- Reactor/Generator-produced
- High Specific Activity
- Low Specific Activity
- Hospital
- Medical Imaging Center
- Other
- ANSTO
- Rosatom
- Eckert & Ziegler
- CNNC
- Curium Pharma
- GE HealthCare
- Jubilant Radiopharma
- Cardinal Health
- IBA
- Sumitomo Heavy Industries
- Sinotau
- Nueclear Healthcare
- DC Pharma
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
- Chapter 1, to describe Radiopharmaceuticals for PET and SPECT Imaging product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top players of Radiopharmaceuticals for PET and SPECT Imaging, with revenue, gross margin, and global market share of Radiopharmaceuticals for PET and SPECT Imaging from 2021 to 2026.
- Chapter 3, the Radiopharmaceuticals for PET and SPECT Imaging competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
- Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Radiopharmaceuticals for PET and SPECT Imaging market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
- Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
- Chapter 12, the key raw materials and key suppliers, and industry chain of Radiopharmaceuticals for PET and SPECT Imaging.
- Chapter 13, to describe Radiopharmaceuticals for PET and SPECT Imaging research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Radiopharmaceuticals for PET and SPECT Imaging by Type
1.3.1 Overview: Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type in 2025
1.3.3 Positron Emitters
1.3.4 Gamma Emitters
1.4 Classification of Radiopharmaceuticals for PET and SPECT Imaging by Produced
1.4.1 Overview: Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced: 2021 Versus 2025 Versus 2032
1.4.2 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Produced in 2025
1.4.3 Cyclotron-produced
1.4.4 Reactor/Generator-produced
1.5 Classification of Radiopharmaceuticals for PET and SPECT Imaging by Specific Activity
1.5.1 Overview: Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity: 2021 Versus 2025 Versus 2032
1.5.2 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Specific Activity in 2025
1.5.3 High Specific Activity
1.5.4 Low Specific Activity
1.6 Global Radiopharmaceuticals for PET and SPECT Imaging Market by Application
1.6.1 Overview: Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Hospital
1.6.3 Medical Imaging Center
1.6.4 Other
1.7 Global Radiopharmaceuticals for PET and SPECT Imaging Market Size & Forecast
1.8 Global Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast by Region
1.8.1 Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Region, (2021-2032)
1.8.3 North America Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
1.8.4 Europe Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
1.8.6 South America Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 ANSTO
2.1.1 ANSTO Details
2.1.2 ANSTO Major Business
2.1.3 ANSTO Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.1.4 ANSTO Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 ANSTO Recent Developments and Future Plans
2.2 Rosatom
2.2.1 Rosatom Details
2.2.2 Rosatom Major Business
2.2.3 Rosatom Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.2.4 Rosatom Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Rosatom Recent Developments and Future Plans
2.3 Eckert & Ziegler
2.3.1 Eckert & Ziegler Details
2.3.2 Eckert & Ziegler Major Business
2.3.3 Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.3.4 Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Eckert & Ziegler Recent Developments and Future Plans
2.4 CNNC
2.4.1 CNNC Details
2.4.2 CNNC Major Business
2.4.3 CNNC Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.4.4 CNNC Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 CNNC Recent Developments and Future Plans
2.5 Curium Pharma
2.5.1 Curium Pharma Details
2.5.2 Curium Pharma Major Business
2.5.3 Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.5.4 Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Curium Pharma Recent Developments and Future Plans
2.6 GE HealthCare
2.6.1 GE HealthCare Details
2.6.2 GE HealthCare Major Business
2.6.3 GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.6.4 GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 GE HealthCare Recent Developments and Future Plans
2.7 Jubilant Radiopharma
2.7.1 Jubilant Radiopharma Details
2.7.2 Jubilant Radiopharma Major Business
2.7.3 Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.7.4 Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Jubilant Radiopharma Recent Developments and Future Plans
2.8 Cardinal Health
2.8.1 Cardinal Health Details
2.8.2 Cardinal Health Major Business
2.8.3 Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.8.4 Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Cardinal Health Recent Developments and Future Plans
2.9 IBA
2.9.1 IBA Details
2.9.2 IBA Major Business
2.9.3 IBA Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.9.4 IBA Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 IBA Recent Developments and Future Plans
2.10 Sumitomo Heavy Industries
2.10.1 Sumitomo Heavy Industries Details
2.10.2 Sumitomo Heavy Industries Major Business
2.10.3 Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.10.4 Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Sumitomo Heavy Industries Recent Developments and Future Plans
2.11 Sinotau
2.11.1 Sinotau Details
2.11.2 Sinotau Major Business
2.11.3 Sinotau Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.11.4 Sinotau Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Sinotau Recent Developments and Future Plans
2.12 Nueclear Healthcare
2.12.1 Nueclear Healthcare Details
2.12.2 Nueclear Healthcare Major Business
2.12.3 Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.12.4 Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Nueclear Healthcare Recent Developments and Future Plans
2.13 DC Pharma
2.13.1 DC Pharma Details
2.13.2 DC Pharma Major Business
2.13.3 DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.13.4 DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 DC Pharma Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Radiopharmaceuticals for PET and SPECT Imaging Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Radiopharmaceuticals for PET and SPECT Imaging by Company Revenue
3.2.2 Top 3 Radiopharmaceuticals for PET and SPECT Imaging Players Market Share in 2025
3.2.3 Top 6 Radiopharmaceuticals for PET and SPECT Imaging Players Market Share in 2025
3.3 Radiopharmaceuticals for PET and SPECT Imaging Market: Overall Company Footprint Analysis
3.3.1 Radiopharmaceuticals for PET and SPECT Imaging Market: Region Footprint
3.3.2 Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Type Footprint
3.3.3 Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value and Market Share by Type (2021-2026)
4.2 Global Radiopharmaceuticals for PET and SPECT Imaging Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2026)
5.2 Global Radiopharmaceuticals for PET and SPECT Imaging Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
6.2 North America Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2021-2032)
6.3 North America Radiopharmaceuticals for PET and SPECT Imaging Market Size by Country
6.3.1 North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2032)
6.3.2 United States Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
6.3.3 Canada Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
6.3.4 Mexico Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
7.2 Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2032)
7.3 Europe Radiopharmaceuticals for PET and SPECT Imaging Market Size by Country
7.3.1 Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2032)
7.3.2 Germany Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7.3.3 France Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7.3.5 Russia Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7.3.6 Italy Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Market Size by Region
8.3.1 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2032)
8.3.2 China Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.3 Japan Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.4 South Korea Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.5 India Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.7 Australia Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
9.2 South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2032)
9.3 South America Radiopharmaceuticals for PET and SPECT Imaging Market Size by Country
9.3.1 South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2032)
9.3.2 Brazil Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
9.3.3 Argentina Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Market Size by Country
10.3.1 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2032)
10.3.2 Turkey Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
10.3.4 UAE Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Radiopharmaceuticals for PET and SPECT Imaging Market Drivers
11.2 Radiopharmaceuticals for PET and SPECT Imaging Market Restraints
11.3 Radiopharmaceuticals for PET and SPECT Imaging Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Radiopharmaceuticals for PET and SPECT Imaging Industry Chain
12.2 Radiopharmaceuticals for PET and SPECT Imaging Upstream Analysis
12.3 Radiopharmaceuticals for PET and SPECT Imaging Midstream Analysis
12.4 Radiopharmaceuticals for PET and SPECT Imaging Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Radiopharmaceuticals for PET and SPECT Imaging by Type
1.3.1 Overview: Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type in 2025
1.3.3 Positron Emitters
1.3.4 Gamma Emitters
1.4 Classification of Radiopharmaceuticals for PET and SPECT Imaging by Produced
1.4.1 Overview: Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced: 2021 Versus 2025 Versus 2032
1.4.2 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Produced in 2025
1.4.3 Cyclotron-produced
1.4.4 Reactor/Generator-produced
1.5 Classification of Radiopharmaceuticals for PET and SPECT Imaging by Specific Activity
1.5.1 Overview: Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity: 2021 Versus 2025 Versus 2032
1.5.2 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Specific Activity in 2025
1.5.3 High Specific Activity
1.5.4 Low Specific Activity
1.6 Global Radiopharmaceuticals for PET and SPECT Imaging Market by Application
1.6.1 Overview: Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Hospital
1.6.3 Medical Imaging Center
1.6.4 Other
1.7 Global Radiopharmaceuticals for PET and SPECT Imaging Market Size & Forecast
1.8 Global Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast by Region
1.8.1 Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Radiopharmaceuticals for PET and SPECT Imaging Market Size by Region, (2021-2032)
1.8.3 North America Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
1.8.4 Europe Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
1.8.6 South America Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 ANSTO
2.1.1 ANSTO Details
2.1.2 ANSTO Major Business
2.1.3 ANSTO Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.1.4 ANSTO Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 ANSTO Recent Developments and Future Plans
2.2 Rosatom
2.2.1 Rosatom Details
2.2.2 Rosatom Major Business
2.2.3 Rosatom Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.2.4 Rosatom Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Rosatom Recent Developments and Future Plans
2.3 Eckert & Ziegler
2.3.1 Eckert & Ziegler Details
2.3.2 Eckert & Ziegler Major Business
2.3.3 Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.3.4 Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Eckert & Ziegler Recent Developments and Future Plans
2.4 CNNC
2.4.1 CNNC Details
2.4.2 CNNC Major Business
2.4.3 CNNC Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.4.4 CNNC Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 CNNC Recent Developments and Future Plans
2.5 Curium Pharma
2.5.1 Curium Pharma Details
2.5.2 Curium Pharma Major Business
2.5.3 Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.5.4 Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Curium Pharma Recent Developments and Future Plans
2.6 GE HealthCare
2.6.1 GE HealthCare Details
2.6.2 GE HealthCare Major Business
2.6.3 GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.6.4 GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 GE HealthCare Recent Developments and Future Plans
2.7 Jubilant Radiopharma
2.7.1 Jubilant Radiopharma Details
2.7.2 Jubilant Radiopharma Major Business
2.7.3 Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.7.4 Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Jubilant Radiopharma Recent Developments and Future Plans
2.8 Cardinal Health
2.8.1 Cardinal Health Details
2.8.2 Cardinal Health Major Business
2.8.3 Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.8.4 Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Cardinal Health Recent Developments and Future Plans
2.9 IBA
2.9.1 IBA Details
2.9.2 IBA Major Business
2.9.3 IBA Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.9.4 IBA Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 IBA Recent Developments and Future Plans
2.10 Sumitomo Heavy Industries
2.10.1 Sumitomo Heavy Industries Details
2.10.2 Sumitomo Heavy Industries Major Business
2.10.3 Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.10.4 Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Sumitomo Heavy Industries Recent Developments and Future Plans
2.11 Sinotau
2.11.1 Sinotau Details
2.11.2 Sinotau Major Business
2.11.3 Sinotau Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.11.4 Sinotau Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Sinotau Recent Developments and Future Plans
2.12 Nueclear Healthcare
2.12.1 Nueclear Healthcare Details
2.12.2 Nueclear Healthcare Major Business
2.12.3 Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.12.4 Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Nueclear Healthcare Recent Developments and Future Plans
2.13 DC Pharma
2.13.1 DC Pharma Details
2.13.2 DC Pharma Major Business
2.13.3 DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
2.13.4 DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 DC Pharma Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Radiopharmaceuticals for PET and SPECT Imaging Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Radiopharmaceuticals for PET and SPECT Imaging by Company Revenue
3.2.2 Top 3 Radiopharmaceuticals for PET and SPECT Imaging Players Market Share in 2025
3.2.3 Top 6 Radiopharmaceuticals for PET and SPECT Imaging Players Market Share in 2025
3.3 Radiopharmaceuticals for PET and SPECT Imaging Market: Overall Company Footprint Analysis
3.3.1 Radiopharmaceuticals for PET and SPECT Imaging Market: Region Footprint
3.3.2 Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Type Footprint
3.3.3 Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value and Market Share by Type (2021-2026)
4.2 Global Radiopharmaceuticals for PET and SPECT Imaging Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2026)
5.2 Global Radiopharmaceuticals for PET and SPECT Imaging Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
6.2 North America Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2021-2032)
6.3 North America Radiopharmaceuticals for PET and SPECT Imaging Market Size by Country
6.3.1 North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2032)
6.3.2 United States Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
6.3.3 Canada Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
6.3.4 Mexico Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
7.2 Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2032)
7.3 Europe Radiopharmaceuticals for PET and SPECT Imaging Market Size by Country
7.3.1 Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2032)
7.3.2 Germany Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7.3.3 France Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7.3.5 Russia Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
7.3.6 Italy Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Market Size by Region
8.3.1 Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2032)
8.3.2 China Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.3 Japan Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.4 South Korea Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.5 India Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
8.3.7 Australia Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
9.2 South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2032)
9.3 South America Radiopharmaceuticals for PET and SPECT Imaging Market Size by Country
9.3.1 South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2032)
9.3.2 Brazil Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
9.3.3 Argentina Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Market Size by Country
10.3.1 Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2032)
10.3.2 Turkey Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
10.3.4 UAE Radiopharmaceuticals for PET and SPECT Imaging Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Radiopharmaceuticals for PET and SPECT Imaging Market Drivers
11.2 Radiopharmaceuticals for PET and SPECT Imaging Market Restraints
11.3 Radiopharmaceuticals for PET and SPECT Imaging Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Radiopharmaceuticals for PET and SPECT Imaging Industry Chain
12.2 Radiopharmaceuticals for PET and SPECT Imaging Upstream Analysis
12.3 Radiopharmaceuticals for PET and SPECT Imaging Midstream Analysis
12.4 Radiopharmaceuticals for PET and SPECT Imaging Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Produced, (USD Million), 2021 & 2025 & 2032
Table 3. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Specific Activity, (USD Million), 2021 & 2025 & 2032
Table 4. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2027-2032) & (USD Million)
Table 7. ANSTO Company Information, Head Office, and Major Competitors
Table 8. ANSTO Major Business
Table 9. ANSTO Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 10. ANSTO Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. ANSTO Recent Developments and Future Plans
Table 12. Rosatom Company Information, Head Office, and Major Competitors
Table 13. Rosatom Major Business
Table 14. Rosatom Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 15. Rosatom Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Rosatom Recent Developments and Future Plans
Table 17. Eckert & Ziegler Company Information, Head Office, and Major Competitors
Table 18. Eckert & Ziegler Major Business
Table 19. Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 20. Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. CNNC Company Information, Head Office, and Major Competitors
Table 22. CNNC Major Business
Table 23. CNNC Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 24. CNNC Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. CNNC Recent Developments and Future Plans
Table 26. Curium Pharma Company Information, Head Office, and Major Competitors
Table 27. Curium Pharma Major Business
Table 28. Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 29. Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Curium Pharma Recent Developments and Future Plans
Table 31. GE HealthCare Company Information, Head Office, and Major Competitors
Table 32. GE HealthCare Major Business
Table 33. GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 34. GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. GE HealthCare Recent Developments and Future Plans
Table 36. Jubilant Radiopharma Company Information, Head Office, and Major Competitors
Table 37. Jubilant Radiopharma Major Business
Table 38. Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 39. Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Jubilant Radiopharma Recent Developments and Future Plans
Table 41. Cardinal Health Company Information, Head Office, and Major Competitors
Table 42. Cardinal Health Major Business
Table 43. Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 44. Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Cardinal Health Recent Developments and Future Plans
Table 46. IBA Company Information, Head Office, and Major Competitors
Table 47. IBA Major Business
Table 48. IBA Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 49. IBA Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. IBA Recent Developments and Future Plans
Table 51. Sumitomo Heavy Industries Company Information, Head Office, and Major Competitors
Table 52. Sumitomo Heavy Industries Major Business
Table 53. Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 54. Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Sumitomo Heavy Industries Recent Developments and Future Plans
Table 56. Sinotau Company Information, Head Office, and Major Competitors
Table 57. Sinotau Major Business
Table 58. Sinotau Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 59. Sinotau Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Sinotau Recent Developments and Future Plans
Table 61. Nueclear Healthcare Company Information, Head Office, and Major Competitors
Table 62. Nueclear Healthcare Major Business
Table 63. Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 64. Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Nueclear Healthcare Recent Developments and Future Plans
Table 66. DC Pharma Company Information, Head Office, and Major Competitors
Table 67. DC Pharma Major Business
Table 68. DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 69. DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. DC Pharma Recent Developments and Future Plans
Table 71. Global Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million) by Players (2021-2026)
Table 72. Global Radiopharmaceuticals for PET and SPECT Imaging Revenue Share by Players (2021-2026)
Table 73. Breakdown of Radiopharmaceuticals for PET and SPECT Imaging by Company Type (Tier 1, Tier 2, and Tier 3)
Table 74. Market Position of Players in Radiopharmaceuticals for PET and SPECT Imaging, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 75. Head Office of Key Radiopharmaceuticals for PET and SPECT Imaging Players
Table 76. Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Type Footprint
Table 77. Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Application Footprint
Table 78. Radiopharmaceuticals for PET and SPECT Imaging New Market Entrants and Barriers to Market Entry
Table 79. Radiopharmaceuticals for PET and SPECT Imaging Mergers, Acquisition, Agreements, and Collaborations
Table 80. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (USD Million) by Type (2021-2026)
Table 81. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Share by Type (2021-2026)
Table 82. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Forecast by Type (2027-2032)
Table 83. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026)
Table 84. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Forecast by Application (2027-2032)
Table 85. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 86. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 87. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 88. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 89. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2026) & (USD Million)
Table 90. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2027-2032) & (USD Million)
Table 91. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 92. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 93. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 94. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 95. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2026) & (USD Million)
Table 96. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2027-2032) & (USD Million)
Table 97. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 98. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 99. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 100. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 101. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2026) & (USD Million)
Table 102. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2027-2032) & (USD Million)
Table 103. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 104. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 105. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 106. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 107. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2026) & (USD Million)
Table 108. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2027-2032) & (USD Million)
Table 109. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 110. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 111. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 112. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 113. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2026) & (USD Million)
Table 114. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2027-2032) & (USD Million)
Table 115. Global Key Players of Radiopharmaceuticals for PET and SPECT Imaging Upstream (Raw Materials)
Table 116. Global Radiopharmaceuticals for PET and SPECT Imaging Typical Customers
Table 1. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Produced, (USD Million), 2021 & 2025 & 2032
Table 3. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Specific Activity, (USD Million), 2021 & 2025 & 2032
Table 4. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2027-2032) & (USD Million)
Table 7. ANSTO Company Information, Head Office, and Major Competitors
Table 8. ANSTO Major Business
Table 9. ANSTO Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 10. ANSTO Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. ANSTO Recent Developments and Future Plans
Table 12. Rosatom Company Information, Head Office, and Major Competitors
Table 13. Rosatom Major Business
Table 14. Rosatom Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 15. Rosatom Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Rosatom Recent Developments and Future Plans
Table 17. Eckert & Ziegler Company Information, Head Office, and Major Competitors
Table 18. Eckert & Ziegler Major Business
Table 19. Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 20. Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. CNNC Company Information, Head Office, and Major Competitors
Table 22. CNNC Major Business
Table 23. CNNC Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 24. CNNC Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. CNNC Recent Developments and Future Plans
Table 26. Curium Pharma Company Information, Head Office, and Major Competitors
Table 27. Curium Pharma Major Business
Table 28. Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 29. Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Curium Pharma Recent Developments and Future Plans
Table 31. GE HealthCare Company Information, Head Office, and Major Competitors
Table 32. GE HealthCare Major Business
Table 33. GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 34. GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. GE HealthCare Recent Developments and Future Plans
Table 36. Jubilant Radiopharma Company Information, Head Office, and Major Competitors
Table 37. Jubilant Radiopharma Major Business
Table 38. Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 39. Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Jubilant Radiopharma Recent Developments and Future Plans
Table 41. Cardinal Health Company Information, Head Office, and Major Competitors
Table 42. Cardinal Health Major Business
Table 43. Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 44. Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Cardinal Health Recent Developments and Future Plans
Table 46. IBA Company Information, Head Office, and Major Competitors
Table 47. IBA Major Business
Table 48. IBA Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 49. IBA Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. IBA Recent Developments and Future Plans
Table 51. Sumitomo Heavy Industries Company Information, Head Office, and Major Competitors
Table 52. Sumitomo Heavy Industries Major Business
Table 53. Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 54. Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Sumitomo Heavy Industries Recent Developments and Future Plans
Table 56. Sinotau Company Information, Head Office, and Major Competitors
Table 57. Sinotau Major Business
Table 58. Sinotau Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 59. Sinotau Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Sinotau Recent Developments and Future Plans
Table 61. Nueclear Healthcare Company Information, Head Office, and Major Competitors
Table 62. Nueclear Healthcare Major Business
Table 63. Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 64. Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Nueclear Healthcare Recent Developments and Future Plans
Table 66. DC Pharma Company Information, Head Office, and Major Competitors
Table 67. DC Pharma Major Business
Table 68. DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Solutions
Table 69. DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. DC Pharma Recent Developments and Future Plans
Table 71. Global Radiopharmaceuticals for PET and SPECT Imaging Revenue (USD Million) by Players (2021-2026)
Table 72. Global Radiopharmaceuticals for PET and SPECT Imaging Revenue Share by Players (2021-2026)
Table 73. Breakdown of Radiopharmaceuticals for PET and SPECT Imaging by Company Type (Tier 1, Tier 2, and Tier 3)
Table 74. Market Position of Players in Radiopharmaceuticals for PET and SPECT Imaging, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 75. Head Office of Key Radiopharmaceuticals for PET and SPECT Imaging Players
Table 76. Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Type Footprint
Table 77. Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Application Footprint
Table 78. Radiopharmaceuticals for PET and SPECT Imaging New Market Entrants and Barriers to Market Entry
Table 79. Radiopharmaceuticals for PET and SPECT Imaging Mergers, Acquisition, Agreements, and Collaborations
Table 80. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (USD Million) by Type (2021-2026)
Table 81. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Share by Type (2021-2026)
Table 82. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Forecast by Type (2027-2032)
Table 83. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026)
Table 84. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Forecast by Application (2027-2032)
Table 85. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 86. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 87. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 88. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 89. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2026) & (USD Million)
Table 90. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2027-2032) & (USD Million)
Table 91. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 92. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 93. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 94. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 95. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2026) & (USD Million)
Table 96. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2027-2032) & (USD Million)
Table 97. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 98. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 99. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 100. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 101. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2026) & (USD Million)
Table 102. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2027-2032) & (USD Million)
Table 103. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 104. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 105. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 106. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 107. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2026) & (USD Million)
Table 108. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2027-2032) & (USD Million)
Table 109. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2021-2026) & (USD Million)
Table 110. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type (2027-2032) & (USD Million)
Table 111. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2021-2026) & (USD Million)
Table 112. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application (2027-2032) & (USD Million)
Table 113. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2021-2026) & (USD Million)
Table 114. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Country (2027-2032) & (USD Million)
Table 115. Global Key Players of Radiopharmaceuticals for PET and SPECT Imaging Upstream (Raw Materials)
Table 116. Global Radiopharmaceuticals for PET and SPECT Imaging Typical Customers
LIST OF FIGURES
Figure 1. Radiopharmaceuticals for PET and SPECT Imaging Picture
Figure 2. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type in 2025
Figure 4. Positron Emitters
Figure 5. Gamma Emitters
Figure 6. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Produced, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Produced in 2025
Figure 8. Cyclotron-produced
Figure 9. Reactor/Generator-produced
Figure 10. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Specific Activity, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Specific Activity in 2025
Figure 12. High Specific Activity
Figure 13. Low Specific Activity
Figure 14. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 15. Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application in 2025
Figure 16. Hospital Picture
Figure 17. Medical Imaging Center Picture
Figure 18. Other Picture
Figure 19. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 20. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 21. Global Market Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 22. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Region (2021-2032)
Figure 23. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Region in 2025
Figure 24. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 25. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 26. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 27. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 28. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 29. Company Three Recent Developments and Future Plans
Figure 30. Global Radiopharmaceuticals for PET and SPECT Imaging Revenue Share by Players in 2025
Figure 31. Radiopharmaceuticals for PET and SPECT Imaging Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 32. Market Share of Radiopharmaceuticals for PET and SPECT Imaging by Player Revenue in 2025
Figure 33. Top 3 Radiopharmaceuticals for PET and SPECT Imaging Players Market Share in 2025
Figure 34. Top 6 Radiopharmaceuticals for PET and SPECT Imaging Players Market Share in 2025
Figure 35. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Share by Type (2021-2026)
Figure 36. Global Radiopharmaceuticals for PET and SPECT Imaging Market Share Forecast by Type (2027-2032)
Figure 37. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Share by Application (2021-2026)
Figure 38. Global Radiopharmaceuticals for PET and SPECT Imaging Market Share Forecast by Application (2027-2032)
Figure 39. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 40. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 41. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Country (2021-2032)
Figure 42. United States Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 43. Canada Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 44. Mexico Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 45. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 46. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 47. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Country (2021-2032)
Figure 48. Germany Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 49. France Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 50. United Kingdom Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 51. Russia Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 52. Italy Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 53. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 54. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 55. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Region (2021-2032)
Figure 56. China Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 57. Japan Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 58. South Korea Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 59. India Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 60. Southeast Asia Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 61. Australia Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 62. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 63. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 64. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Country (2021-2032)
Figure 65. Brazil Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 66. Argentina Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 67. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 68. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 69. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Country (2021-2032)
Figure 70. Turkey Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 71. Saudi Arabia Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 72. UAE Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 73. Radiopharmaceuticals for PET and SPECT Imaging Market Drivers
Figure 74. Radiopharmaceuticals for PET and SPECT Imaging Market Restraints
Figure 75. Radiopharmaceuticals for PET and SPECT Imaging Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Radiopharmaceuticals for PET and SPECT Imaging Industrial Chain
Figure 78. Methodology
Figure 79. Research Process and Data Source
Figure 1. Radiopharmaceuticals for PET and SPECT Imaging Picture
Figure 2. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type in 2025
Figure 4. Positron Emitters
Figure 5. Gamma Emitters
Figure 6. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Produced, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Produced in 2025
Figure 8. Cyclotron-produced
Figure 9. Reactor/Generator-produced
Figure 10. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Specific Activity, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Specific Activity in 2025
Figure 12. High Specific Activity
Figure 13. Low Specific Activity
Figure 14. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 15. Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application in 2025
Figure 16. Hospital Picture
Figure 17. Medical Imaging Center Picture
Figure 18. Other Picture
Figure 19. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 20. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 21. Global Market Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 22. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Region (2021-2032)
Figure 23. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Region in 2025
Figure 24. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 25. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 26. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 27. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 28. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 29. Company Three Recent Developments and Future Plans
Figure 30. Global Radiopharmaceuticals for PET and SPECT Imaging Revenue Share by Players in 2025
Figure 31. Radiopharmaceuticals for PET and SPECT Imaging Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 32. Market Share of Radiopharmaceuticals for PET and SPECT Imaging by Player Revenue in 2025
Figure 33. Top 3 Radiopharmaceuticals for PET and SPECT Imaging Players Market Share in 2025
Figure 34. Top 6 Radiopharmaceuticals for PET and SPECT Imaging Players Market Share in 2025
Figure 35. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Share by Type (2021-2026)
Figure 36. Global Radiopharmaceuticals for PET and SPECT Imaging Market Share Forecast by Type (2027-2032)
Figure 37. Global Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Share by Application (2021-2026)
Figure 38. Global Radiopharmaceuticals for PET and SPECT Imaging Market Share Forecast by Application (2027-2032)
Figure 39. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 40. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 41. North America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Country (2021-2032)
Figure 42. United States Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 43. Canada Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 44. Mexico Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 45. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 46. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 47. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Country (2021-2032)
Figure 48. Germany Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 49. France Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 50. United Kingdom Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 51. Russia Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 52. Italy Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 53. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 54. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 55. Asia-Pacific Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Region (2021-2032)
Figure 56. China Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 57. Japan Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 58. South Korea Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 59. India Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 60. Southeast Asia Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 61. Australia Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 62. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 63. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 64. South America Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Country (2021-2032)
Figure 65. Brazil Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 66. Argentina Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 67. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Type (2021-2032)
Figure 68. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Application (2021-2032)
Figure 69. Middle East & Africa Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Country (2021-2032)
Figure 70. Turkey Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 71. Saudi Arabia Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 72. UAE Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 73. Radiopharmaceuticals for PET and SPECT Imaging Market Drivers
Figure 74. Radiopharmaceuticals for PET and SPECT Imaging Market Restraints
Figure 75. Radiopharmaceuticals for PET and SPECT Imaging Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Radiopharmaceuticals for PET and SPECT Imaging Industrial Chain
Figure 78. Methodology
Figure 79. Research Process and Data Source
